Daytrana Approval For Adolescents Gives Shire's ADHD Drug A New Lease On Life
This article was originally published in The Pink Sheet Daily
Sales of the patch were down 10 percent last year due to recalls caused by manufacturing problems.
You may also be interested in...
Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion
FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.
Did Vyvanse Internet Ads Draw A Subpoena? Shire ADHD Promotions Get Government's Attention
HHS' request for documents comes as Shire launches new marketing campaigns and co-promotion with GlaxoSmithKline.
FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs
FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media